Kadmos Capital
VC Fund
London, United Kingdom
Kadmos Capital is a VC fund in London focused on Health Care and Biotechnology. The intersection of science, technology and ambition is where you’ll find Kadmos Capital, with our track record of successful tech investments and instinct for identifying the most exciting entrepreneurs. Our optimism isn’t shaken by the daunting challenges we face in an unstable world, it is strengthened. The biggest problems demand the most ambitious and ingenious solutions. With the pace of change now faster than ever, it’s vital to back the high-impact technologies that will deliver those solutions. At Kadmos Capital, that is where we are invested.
- Total investments:
- 31
- Last investment:
- Lead investor:
- 19%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Kadmos Capital invests in
Stages Kadmos Capital invests in
Countries Kadmos Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $2.5M–$16M
- Series A
- $5M–$13M
- Venture - Series Unknown
- $2.1M–$8.7M
Investment Focus
Industry
- Health Care 8 (26%)
- Biotechnology 8 (26%)
- Artificial Intelligence 6 (19%)
- Information Technology 5 (16%)
- Software 3 (10%)
Stage
- Seed 17 (55%)
- Series A 5 (16%)
- Venture - Series Unknown 2 (6%)
- Pre-Seed 1 (3%)
- Series B 1 (3%)
Country
- United Kingdom 16 (52%)
- France 2 (6%)
- Switzerland 2 (6%)
- Luxembourg 1 (3%)
- The Netherlands 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
John Gebeily
Operating Partner
|
Operating Partner | Total investments: 7 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| InTouchNow provides outsourced multi-channel answering services. | $3.1M / Seed / Sep 21, 2026 | ||
| Big Picture Bio develops a hybrid multi-agent artificial intelligence platform to design systems-level therapies and cancer combination treatments. The company simulates how dynamic complex diseases behave and interact to optimize drug combinations and sequencing from billions of possibilities, aiming to minimize residual disease. | $2M / Pre-Seed / Sep 17, 2026 | ||
| Preventive healthcare platform that equips people with personalized insights and expert guidance for proactive whole-body health | $3.8M / Seed / Sep 14, 2026 | ||
| Stability AI is an artificial intelligence-driven visual art startup that designs and implements open AI tools. The company focuses on creating open models for various media types, including image, video, 3D, and audio, with applications also targeting enterprise-level needs. Stability AI fosters a vibrant community involving experts and partnersworldwide, enhancing collaboration in developing AI tools. | $76M / Series B / Aug 25, 2026 | ||
| Pathway is a game-changing dev tool for enterprise clients, enabling real-time machine learning on live event streams. They are a unified source of truth from raw data, in logistics and other industries. Pathway is created by people who worked in the best AI labs in the world, ex-googlers, the world's top competitive programmers, and expertsin machine learning applied to logistics. They bring automation and scalability which make AI more accessible, thus driving the costs down. | $30M / Seed / Aug 11, 2026 | ||
| Antiverse is a new type of antibody discovery company accelerating drug development. Its platform exists at the intersection of structural biology, machine learning, and medicine to enable breakthroughs to happen more quickly and cost-effectively. It is dedicated to engineering the future of drug development to change the course of people'slives. | $9.3M / Series A / Mar 03, 2026 | ||
| Can you slow down your inner body clock? At GlycanAge we’ve proven you can! How? By analysing over 150,000 individuals across 20 years of research from our world leading scientists.Our studies show that well managed dietary improvements, healthy weight loss, and exercise can tangibly improve your biological age. GlycanAge is the only biologicalage test proven to respond to lifestyle changes. We’ve made your choices measurable so you can stay healthier and younger for longer. | $8.7M / Venture - Series Unknown / Dec 18, 2025 | ||
| MovaLive aims to bring about a transition in the field of Assisted Reproductive Technology (ART) | $2.1M / Venture - Series Unknown / Nov 07, 2025 | ||
| Scindo is a cleantech start-up harnessing the power of enzymes to recycle the unrecyclables. We are targeting plastics that cannot be efficiently recycled with current methodologies, to turn them into high-value molecules that can be used in a plethora of industries. We are creating a more circular economy for plastics by developing an alternativeto landfills and incineration. | $5.4M / Seed / Sep 23, 2025 | ||
| OutSee creates cutting-edge computational methods for genomics for the development of therapeutic targets and precision medicine. | $3.4M / Seed / Jun 24, 2025 | ||
| See all 31 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Kadmos Capital invest in?
Kadmos Capital invests primarily in Health Care, Biotechnology and Artificial Intelligence startups, most often at Seed and Series A stage. Most of the 31 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Kadmos Capital invest in?
Kadmos Capital typically joins rounds of $2.5M–$16M at Seed, $5M–$13M at Series A and $2.1M–$8.7M at Venture - Series Unknown. These are whole funding-round sizes, not Kadmos Capital's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Kadmos Capital took part in.
How do I contact Kadmos Capital?
Public channels for Kadmos Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Kadmos Capital?
The team at Kadmos Capital includes John Gebeily (Operating Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
